Loading stock data…
Pharvaris N.V (PHVS)
$34.17+0.91 (+2.74%)
Market ClosedLast close Jul 24
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pharvaris N.V. in the Healthcare sector is trading at $34.17 with a market capitalization of $2.2B. Wall Street consensus targets $47.02 (14 analysts), implying a +37.6% move over the next 12 months. The stock is currently near its 52-week high of $36.60, remaining 23.6% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +37.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$44.27M↑ | -$47.60M↓ | -$39.66M↑ | -$40.37M↑ | -$42.19M |
| Net Income | -$39.20M↑ | -$46.74M↓ | -$37.14M↑ | -$45.48M↑ | -$46.34M |
Peer Comparison
JNJUNHPFE
Fundamentals
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.17B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-71.32%
Volume
Today's trading volume
253,059
Recent News
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?
This late-stage biotech innovator in rare disease therapies reported significant insider selling amid strong one-year share price gains.
Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy
Does Pharvaris N.V. (PHVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
IBM downgraded, Cava upgraded: Wall Street's top analyst calls
IBM downgraded, Cava upgraded: Wall Street's top analyst calls
Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade
The mean of analysts' price targets for Pharvaris (PHVS) points to a 36.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why This Biotech, Up 12% Since Its Breakout, Yo-Yoed On A Key FDA Development
Pharvaris stock jumped early Monday, but closed down, after the FDA agreed to review the company's treatment for a serious swelling disease.